CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 55 target
Drug / intervention
Chidamide combined with Cisplatindrug
Likely dose
Chidamide combined with Cisplatin 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04192903
NCT04192903Phase 2Unknown
CompareCT.gov

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

Fudan University·interventional·Posted Dec 10, 2019·Updated Apr 20, 2022

In Brief

A Phase 2 clinical trial evaluating Chidamide combined with Cisplatin for Triple-negative Breast Cancer. Targeting 55 participants across 2 sites.

Detailed Summary

The goal of this clinical trial is to evaluate therapeutic efficacy and safety of Chidamide combined with Cisplatin for relapsed or metastatic triple-negative breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple-negative Breast Cancer
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
2020202120222023202420252026
First PostedDec 10, 2019
Enrollment StartDec 25, 2019
Primary CompletionJun 1, 2022
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 6.6 years ago

Interventions

Chidamide combined with Cisplatindrug

Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off